Literature DB >> 2820608

Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility.

R E Weishaar1, D C Kobylarz-Singer, R P Steffen, H R Kaplan.   

Abstract

Ventricular muscle contains a low Km, cyclic AMP-specific form of phosphodiesterase (PDE III), which is believed to represent the site of action for several of new cardiotonic agents including imazodan (CI-914), amrinone, cilostamide, and enoximone. However, species differences in the inotropic response to these agents have raised questions about the relationship between PDE III inhibition and cardiotonic activity. The present study demonstrates that these differences can be accounted for by the presence of two subclasses of PDE III in ventricular muscle and variations in the intracellular localization of these two enzymes. For these experiments, PDE III was initially isolated from canine, guinea pig, and rat left ventricular muscle. The results demonstrate that canine left ventricular muscle contains two functional subclasses of PDE III: an imazodan-sensitive form, which is membrane bound, and an imazodan-insensitive form, which is soluble. Although only weakly inhibited by imazodan, this latter enzyme is potently inhibited by the selective PDE III inhibitors, Ro 20-1724 and rolipram. Guinea pig ventricular muscle also contains the imazodan-sensitive subclass of PDE III. Unlike canine left ventricle, however, thi enzyme is soluble in the guinea pig. No membrane-bound subclass of PDE III was observed in the guinea pig. Rat left ventricle possesses only the soluble form of PDE III, which apparently represents a mixture of the imazodan-sensitive and imazodan-insensitive subclasses of PDE III. Measurement of in vivo contractility in these three species showed that imazodan exerts a potent positive inotropic effect only in the dog, in which the imazodan-sensitive subclass of PDE III is membrane bound.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820608     DOI: 10.1161/01.res.61.4.539

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  48 in total

1.  Species differences in localization of cardiac cAMP-phosphodiesterase activity: a cytochemical study.

Authors:  L Okruhlicová; N Tribulová; J Styk; A Eckly; C Lugnier; J Slezk
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

Review 2.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.

Authors:  M A Movsesian; C J Smith; J Krall; M R Bristow; V C Manganiello
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle.

Authors:  M Galvan; C Schudt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

5.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

6.  Proceedings of the British Pharmacological Society. University of Manchester, 13-15 September 1989.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

Review 7.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 8.  Studies on the mechanism of action of the bipyridine milrinone on the heart.

Authors:  A E Farah; C J Frangakis
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 9.  Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.

Authors:  J Tauke; D Han; M Gheorghiade
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

10.  The negative inotropic effect of neuropeptide Y on the ventricular cardiomyocyte.

Authors:  H M Piper; B C Millar; B J McDermott
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.